Macquarie Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.3M | Buy |
20,943
+4,896
| +31% | +$1.48M | 0.03% | 362 |
|
|
2026
Q1 | $5.31M | Sell |
16,047
-9,234
| -37% | -$3.14M | 0.03% | 342 |
|
|
2025
Q4 | $10.1M | Sell |
25,281
-623,063
| -96% | -$276M | 0.04% | 285 |
|
|
2025
Q3 | $296M | Buy |
648,344
+48,233
| +8% | +$19.6M | 0.35% | 37 |
|
|
2025
Q2 | $196M | Buy |
600,111
+527,519
| +727% | +$146M | 0.24% | 71 |
|
|
2025
Q1 | $19.6M | Buy |
72,592
+11,928
| +20% | +$3.07M | 0.02% | 660 |
|
|
2024
Q4 | $14.3M | Sell |
60,664
-11,952
| -16% | -$3.14M | 0.02% | 732 |
|
|
2024
Q3 | $20M | Buy |
72,616
+13,161
| +22% | +$3.43M | 0.02% | 668 |
|
|
2024
Q2 | $14.4M | Buy |
59,455
+3,548
| +6% | +$560K | 0.02% | 732 |
|
|
2024
Q1 | $8.36M | Buy |
55,907
+8,890
| +19% | +$1.48M | 0.01% | 862 |
|
|
2023
Q4 | $9M | Buy |
47,017
+1,111
| +2% | +$189K | 0.01% | 848 |
|
|
2023
Q3 | $8.13M | Buy |
45,906
+882
| +2% | +$168K | 0.01% | 830 |
|
|
2023
Q2 | $8.55M | Sell |
45,024
-705
| -2% | -$140K | 0.01% | 831 |
|
|
2023
Q1 | $9.16M | Buy |
45,729
+511
| +1% | +$107K | 0.01% | 822 |
|
|
2022
Q4 | $10.7M | Buy |
45,218
+934
| +2% | +$199K | 0.01% | 820 |
|
|
2022
Q3 | $8.86M | Buy |
44,284
+1,352
| +3% | +$258K | 0.01% | 859 |
|
|
2022
Q2 | $6.26M | Sell |
42,932
-279
| -0.6% | -$39.6K | 0.01% | 980 |
|
|
2022
Q1 | $7.06M | Buy |
43,211
+96
| +0.2% | +$14.6K | 0.01% | 1023 |
|
|
2021
Q4 | $7.31M | Sell |
43,115
-10,478
| -20% | -$1.95M | 0.01% | 1021 |
|
|
2021
Q3 | $10.1M | Hold |
53,593
| – | – | 0.01% | 920 |
|
|
2021
Q2 | $9.09M | Buy |
53,593
+100
| +0.2% | +$14.6K | 0.01% | 964 |
|
|
2021
Q1 | $7.55M | Buy |
53,493
+10,198
| +24% | +$1.53M | 0.01% | 802 |
|
|
2020
Q4 | $5.63M | Sell |
43,295
-842
| -2% | -$112K | 0.01% | 856 |
|
|
2020
Q3 | $6.43M | Sell |
44,137
-10,610
| -19% | -$1.51M | 0.01% | 757 |
|
|
2020
Q2 | $8.11M | Sell |
54,747
-1,556
| -3% | -$210K | 0.01% | 667 |
|
|
2020
Q1 | $6.13M | Sell |
56,303
-2,875
| -5% | -$332K | 0.01% | 670 |
|
|
2019
Q4 | $6.82M | Buy |
59,178
+103
| +0.2% | +$10.3K | 0.01% | 727 |
|
|
2019
Q3 | $4.75M | Sell |
59,075
-3,213
| -5% | -$254K | 0.01% | 780 |
|
|
2019
Q2 | $4.52M | Buy |
62,288
+4,215
| +7% | +$323K | 0.01% | 802 |
|
|
2019
Q1 | $5.43M | Buy |
58,073
+220
| +0.4% | +$18.4K | 0.01% | 762 |
|
|
2018
Q4 | $4.22M | Buy |
57,853
+438
| +0.8% | +$33.7K | 0.01% | 790 |
|
|
2018
Q3 | $5.03M | Buy |
57,415
+784
| +1% | +$78.9K | 0.01% | 790 |
|
|
2018
Q2 | $5.58M | Buy |
56,631
+13,747
| +32% | +$1.36M | 0.01% | 754 |
|
|
2018
Q1 | $5.11M | Buy |
42,884
+1,958
| +5% | +$252K | 0.01% | 744 |
|
|
2017
Q4 | $5.2M | Buy |
40,926
+27,914
| +215% | +$3.51M | 0.01% | 776 |
|
|
2017
Q3 | $1.53M | Sell |
13,012
-2,649
| -17% | -$226K | ﹤0.01% | 1068 |
|
|
2017
Q2 | $1.25M | Sell |
15,661
-1,608
| -9% | -$103K | ﹤0.01% | 1099 |
|
|
2017
Q1 | $885K | Sell |
17,269
-486
| -3% | -$22.5K | ﹤0.01% | 1209 |
|
|
2016
Q4 | $665K | Buy |
17,755
+1,614
| +10% | +$67.6K | ﹤0.01% | 1266 |
|
|
2016
Q3 | $1.09M | Sell |
16,141
-4,002
| -20% | -$282K | ﹤0.01% | 1125 |
|
|
2016
Q2 | $1.12M | Buy |
20,143
+19,243
| +2,138% | +$1.21M | ﹤0.01% | 1114 |
|
|
2016
Q1 | $56K | Hold |
900
| – | – | ﹤0.01% | 1466 |
|
|
2015
Q4 | $85K | Hold |
900
| – | – | ﹤0.01% | 1425 |
|
|
2015
Q3 | $72K | Sell |
900
-14,384
| -94% | -$1.6M | ﹤0.01% | 1511 |
|
|
2015
Q2 | $1.83M | Sell |
15,284
-4,587
| -23% | -$548K | ﹤0.01% | 1046 |
|
|
2015
Q1 | $2.08M | Sell |
19,871
-6,167
| -24% | -$625K | ﹤0.01% | 1013 |
|
|
2014
Q4 | $2.53M | Sell |
26,038
-1,994
| -7% | -$185K | 0.01% | 944 |
|
|
2014
Q3 | $2.19M | Sell |
28,032
-2,000
| -7% | -$129K | ﹤0.01% | 973 |
|
|
2014
Q2 | $1.9M | Buy |
30,032
+2,828
| +10% | +$168K | ﹤0.01% | 1057 |
|
|
2014
Q1 | $1.83M | Sell |
27,204
-15,646
| -37% | -$1.21M | ﹤0.01% | 1040 |
|
|
2013
Q4 | $2.76M | Buy |
42,850
+16,759
| +64% | +$1,000K | ﹤0.01% | 849 |
|
|
2013
Q3 | $1.67M | Buy |
26,091
+8,091
| +45% | +$403K | ﹤0.01% | 1015 |
|
|
2013
Q2 | $558K | Buy |
+18,000
| New | +$479K | ﹤0.01% | 1266 |
|
Other funds holding ALNY
Macquarie Group's ALNY Position: Q2 2026 in Review
Macquarie Group increased its Alnylam Pharmaceuticals (ALNY) stake by 31% in Q2 2026, buying an estimated $1.48M and bringing the position to 20,943 shares worth $6.3M. The position accounts for 0.03% of the portfolio, ranked #362.
Macquarie Group first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $296M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Macquarie Group held 20,943 shares of Alnylam Pharmaceuticals worth $6.3M as of Q2 2026.
- Macquarie Group bought 4,896 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.48M.
- Alnylam Pharmaceuticals made up 0.03% of Macquarie Group's portfolio in Q2 2026, its #362 holding.
- Macquarie Group first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Macquarie Group's Alnylam Pharmaceuticals position peaked at $296M in Q3 2025.
- 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.